R&D Catching the signals sooner: AI’s role in proactive pharmaco... AI is not a replacement for medical judgement. Rather, it enables a human-guided, scientifically grounded approach.
R&D Inspection readiness is now a commercial question Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.
Digital Sponsored Antiviral development in the age of AI: From pre-IND to earl... hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.
Digital The growing use of synthetic data in modern pharma The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.
Digital AI is exposing a new digital maturity divide in pharma busin... As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.
Digital Sponsored 4 Questions pharma leaders can’t skip before letting AI act Nataliya Andreychuk explains what teams must do before letting AI act on their behalf, and how that groundwork becomes a competitive advantage.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.